The Family Firm’s Alaunos Therapeutics TCRT Stock Holding History

The Family Firm’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1	Closed	-$5	–	768
2024 Q2	$5	Buy	+1	New	+$12	﹤0.01%	891

Other funds holding TCRT

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

SWM

Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

The Family Firm's TCRT Position: Q3 2024 in Review

The Family Firm sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 1 share — an estimated $5 sold.

The Family Firm first reported a position in TCRT in Q2 2024 and held it in 1 quarter. The position peaked at $5 in Q2 2024. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

The Family Firm reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
The Family Firm sold 1 Alaunos Therapeutics share in Q3 2024, an estimated $5.
The Family Firm first reported a position in Alaunos Therapeutics in Q2 2024 and held it in 1 quarter.
The Family Firm's Alaunos Therapeutics position peaked at $5 in Q2 2024.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on The Family Firm's 13F filing for Q3 2024, filed 17 Oct 2024.